Home » Stocks » SBBP

Strongbridge Biopharma PLC (SBBP)

Stock Price: $2.31 USD 0.03 (1.32%)
Updated May 18, 2021 1:06 PM EDT - Market open
Market Cap 159.51M
Revenue (ttm) 32.44M
Net Income (ttm) -44.19M
Shares Out 67.38M
EPS (ttm) -0.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 18
Last Price $2.31
Previous Close $2.28
Change ($) 0.03
Change (%) 1.32%
Day's Open 2.30
Day's Range 2.28 - 2.34
Day's Volume 112,413
52-Week Range 1.87 - 4.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of -10.00% and 2.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 days ago - Zacks Investment Research

Shares of Strongbridge Biopharma (NASDAQ:SBBP) fell 3.7% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 42.11% over the past year to ($0.11), whic...

6 days ago - Benzinga

~ Reports KEVEYIS ®  (dichlorphenamide) First Quarter 2021 Revenue of $8.4 Million, a 25 Percent Increase Compared to $6.7 Million of Revenue During First Quarter of 2020 ~

6 days ago - GlobeNewsWire

On Wednesday, May 12, Strongbridge Biopharma (NASDAQ:SBBP) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

1 week ago - Benzinga

DUBLIN, Ireland and TREVOSE, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerci...

1 week ago - GlobeNewsWire

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

RECORLEV® (levoketoconazole) Treatment Demonstrates Clinically Meaningful Improvements in Cortisol Control and Clinical Benefit in Patients with Cushing's Syndrome and Comorbid Diabetes Mellitus

1 month ago - GlobeNewsWire

Strongbridge Biopharma plc (NASDAQ: SBBP) has announced detailed results from the previously reported Phase 3 LOGICS study of Recorlev (levoketoconazole) in patients with endogenous Cushing's syndrome. ...

1 month ago - Benzinga

~ As Previously Reported, LOGICS Met its Primary Endpoint with Statistical Significance ~

1 month ago - GlobeNewsWire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: INFI, NBEV, FINV, SVRA
1 month ago - 24/7 Wall Street

DUBLIN, Ireland and TREVOSE, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...

2 months ago - GlobeNewsWire

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 15.38% and 1.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Strongbridge Biopharma (NASDAQ:SBBP) moved higher by 0.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 56.00% over the past year ...

2 months ago - Benzinga

~ Submitted New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing's Syndrome to U.S. Food & Drug Administration ~

2 months ago - GlobeNewsWire

Strongbridge Biopharma plc (NASDAQ: SBBP) has submitted a marketing application seeking approval for Recorlev (levoketoconazole) for the treatment of endogenous Cushing's syndrome, to the FDA. Endogenou...

2 months ago - Benzinga

~ RECORLEV® (levoketoconazole) New Drug Application is Supported by Previously-Reported Positive and Statistically Significant Results from the Phase 3 SONICS and LOGICS Studies ~

2 months ago - GlobeNewsWire

DUBLIN, Ireland and TREVOSE, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...

2 months ago - GlobeNewsWire

DUBLIN, Ireland and TREVOSE, Pa., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...

3 months ago - GlobeNewsWire

~ Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Percent Increase over 2019 Rev...

4 months ago - GlobeNewsWire

~ RECORLEV™ (levoketoconazole) Treatment Resulted in Significantly Improved Clinician-Assessed Signs and Symptoms and Patient-Reported Outcomes of Cushing's Syndrome ~ ~ RECORLEV™ (levoketoconazole) Tre...

5 months ago - GlobeNewsWire

The shares of small-cap biopharma concern are finally seeing some momentum as they rally off oversold levels. The company posted better-than-expected Q3 results in late October and have some potential c...

5 months ago - Seeking Alpha

DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerci...

6 months ago - GlobeNewsWire

Strongbridge Biopharma plc (SBBP) CEO John Johnson on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 20.00% and 11.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

~ Company on Track to Submit New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the FDA in the First Quarter of 2021 Following the Reporting of Positive Top-line Data from the LOGICS Study i...

6 months ago - GlobeNewsWire

DUBLIN, Ireland and TREVOSE, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...

6 months ago - GlobeNewsWire

DUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and comm...

8 months ago - GlobeNewsWire

DUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and comm...

8 months ago - GlobeNewsWire

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Strongbridge Biopharma plc ("Strongbridge" or the "Company") (NYSE: SBBP).

8 months ago - PRNewsWire

After reporting positive Recorlev Phase 3 top line data, SBBP management demonstrated incredible confidence by guiding investors to expect $250MM-$350MM/year in peak Recorlev sales/year.

8 months ago - Seeking Alpha

~ Company Reported Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome; To Vi...

8 months ago - GlobeNewsWire

~ LOGICS Study Met Primary Endpoint with High Statistical Significance; Results at the End of the Randomized-Withdrawal Phase of the Study Demonstrated that Withdrawing Patients to Placebo Resulted in a...

8 months ago - GlobeNewsWire

Recorlev's Cushing's disease phase 3 topline data is due 9/2020. If the data looks good, NDA submission follows. If the data does not look good, SBBP options are very limited.

9 months ago - Seeking Alpha

Strongbridge Biopharma plc's (SBBP) CEO John Johnson on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 40.00% and 27.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

~ Reports KEVEYIS® (dichlorphenamide) Second Quarter 2020 Revenue of $7.8 Million, a 28 Percent Increase Compared to $6.1 Million During Second Quarter of 2019 ~

9 months ago - GlobeNewsWire

DUBLIN, Ireland and TREVOSE, Pa., July 28, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and comme...

9 months ago - GlobeNewsWire

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

DUBLIN, Ireland and TREVOSE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and comme...

10 months ago - GlobeNewsWire

Company Expects to Report Topline Phase 3 LOGICS Study Results During the Third Quarter of 2020 Company Expects to Report Topline Phase 3 LOGICS Study Results During the Third Quarter of 2020

10 months ago - GlobeNewsWire

DUBLIN, Ireland and TREVOSE, Pa., May 20, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commer...

11 months ago - GlobeNewsWire

Strongbridge Biopharma Attractive Valuation With Catalysts Approaching

1 year ago - Seeking Alpha

Company Expects to Report Top-Line LOGICS Results During the Third Quarter of 2020 Company Expects to Report Top-Line LOGICS Results During the Third Quarter of 2020

1 year ago - GlobeNewsWire

Strongbridge Biopharma plc (SBBP) Management on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 5.00% and 11.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Shares of Strongbridge Biopharma (NASDAQ:SBBP) were flat in pre-market trading after the company reported Q1 results.

1 year ago - Benzinga

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

DUBLIN, Ireland and TREVOSE, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commer...

1 year ago - GlobeNewsWire

Strongbridge Biopharma plc (SBBP) Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 7.41% and 12.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

About SBBP

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somato... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2015
CEO
Matthew Pauls
Employees
72
Stock Exchange
NASDAQ
Ticker Symbol
SBBP
Full Company Profile

Financial Performance

In 2020, SBBP's revenue was $30.73 million, an increase of 41.54% compared to the previous year's $21.71 million. Losses were -$45.08 million, -8.85% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for SBBP stock is "Strong Buy." The 12-month stock price forecast is 8.00, which is an increase of 246.32% from the latest price.

Price Target
$8.00
(246.32% upside)
Analyst Consensus: Strong Buy